Introduction
Antiepileptic drugs (AEDs) have a prominent role in the treatment of several types of chronic pain. Gabapentin and pregabalin are recommended as first-line treatments for various neuropathic pain conditions, carbamazepine and oxcarbazepine are commonly used in trigeminal neuralgia, and certain AEDs are considered second-or third-line treatments for neuropathic pain [3, 7, 11, 12, 25] . In addition, pregabalin is recommended for fibromyalgia [8] , and topiramate and valproic acid are considered first-line treatments for migraine prophylaxis [13, 33] .
Given the role played by AEDs in pain treatment, it is important to consider recent research and recommendations regarding AEDs and suicidality, which includes both suicidal behavior and suicidal ideation [17, 31, 37] . On the basis of a meta-analysis, the US Food and Drug Administration (FDA) concluded that AED treatment for any indication is associated with an increased risk of suicidality [37] ; as a consequence, AED product information was changed to include warnings about this risk. After conducting an independent review, the European Medicines Agency (EMA) also instituted warnings about AEDs and suicidality [22, 27] .
In evaluating the risk of suicidality associated with AEDs, an important consideration is that several conditions for which they are prescribed also have an increased suicide risk, including epilepsy [10,20] and certain psychiatric disorders [6,14,21]. Chronic pain is also associated with suicidality [32,34,36], and as many as 50% of patients with chronic pain have comorbid depression [5], a well-established risk factor for suicide [9] .
The objective of this article is to review recent research on suicidality and AEDs and to discuss its implications for the treatment of neuropathic pain and fibromyalgia. The role of AEDs in migraine treatment, which is prophylactic rather than symptomatic, is beyond the scope of this review, as is AED treatment in seizure disorders and in psychiatric conditions for their mood-stabilizing effects.
Methods
A Medline search exploding the MESH terms ''suicide'' and ''anticonvulsants'' and a PubMed search were conducted. Studies included in this review were generally limited to those that appeared in 2008 and after, and considered relevant to FDA and EMA warnings. Separate searches were performed to gather data from FDA, EMA, and other sources. Relevant studies are discussed below and summarized in Table 1 .
Results
The FDA conducted a meta-analysis that focused on 199 placebo-controlled trials of 11 AEDs. The treatment groups contained a total 27,863 patients, and the placebo groups contained 16,029 patients [37] . Approximately 25% of these patients had epilepsy, 27% had psychiatric disorders, including mood disorders and schizophrenia, and 48% were classified as having ''other'' conditions, including obesity, insomnia, migraine, and various pain disorders. The Columbia Classification Algorithm of Suicide Assessment was used for retrospectively assessing suicidal behavior and ideation [31] . Based on adjusted risk estimates, 0.43% of patients in the AED groups had suicidal behavior or ideation vs 0.24% in the placebo groups. The FDA concluded that AEDs appeared to increase the risk of suicidality regardless of treatment indication, specific AED, or mechanism of action, and that increased risk was observed as early as 1 week after treatment initiation and continued for at least 24 weeks. When treatment indications were assessed individually, the only group with a significantly increased risk was epilepsy patients, for whom the odds ratio was 1.80 (95% confidence interval 1.24-2.66). However, the odds ratio for the ''other'' group in the FDA meta-analysis, which included patients with various pain conditions, was 1.87 (95% confidence interval 0.81-4.76) ( Table 1) ; patients in this group were taking divalproex, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, topiramate, or zonisamide. As discussed below, methodological limitations of the adverse event data used in this study hamper the ability to draw causal inferences.
Olesen et al. [28] conducted an analysis of 6780 suicides and a cohort study of 169,725 treatment-naïve patients in Denmark. The
